Literature DB >> 28511796

Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5.

Guang-Jun Hao1, Yan-Hui Ding1, Hui Wen1, Xiao-Feng Li1, Wei Zhang1, Hu-Yan Su1, Dong-Mei Liu1, Nian-Lin Xie2.   

Abstract

Deregulation of the microRNAs (miRNAs), a cluster of important posttranscriptional regulators, has been frequently associated with lung cancer (LCa). However, the emerging mechanism for how miRNAs is linked causally in the development of LCa chemoresistance is poorly understood. Herein, we established for the time the up-regulation of miR-369-3p in cisplatin (DDP)-resistant nonsmall cell lung cancer (NSCLC) tissues and cells. Its deregulation was found to be correlated to the magnitude of malignancy in well-characterized LCa cells. Functionally, inhibition of miR-369-3p sensitized LCa cells to DDP and suppressed the invasive capability in the presence of DDP treatment, whereas miR-369-3p overexpression promoted DDP resistance and thereby enhanced LCa cells invasiveness. Mechanistically, bioinformatics coupled with luciferase and gain-of-function, loss-of-function assays revealed that miR-369-3p may regulate DDP chemoresistance by directly targeting the 3' untranslated region (UTR) of human solute carrier 35F5 (SLC35F5), as application of miR-369-3p inhibitors or reintroduction of epigenetically silenced SLC35F5 both individually sensitized LCa cells to DDP, but combined treatment with miR-369-3p inhibitors and SLC35F5 overexpression failed to sensitized LCa cells further to DDP-elicited cell death. Our results provide evidence that the oncomiR effect of miR-369-3p may be mediated through disrupting the nucleotide sugar transportation and that SLC35F5 is a key effector of this chemoresistance-promoting activity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Cisplatin; Nonsmall cell lung cancer (NSCLC); SLC35F5; miR-369-3p

Mesh:

Substances:

Year:  2017        PMID: 28511796     DOI: 10.1016/j.bbrc.2017.05.075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Retracted Article: Long noncoding RNA ANRIL knockdown increases sensitivity of non-small cell lung cancer to cisplatin by regulating the miR-656-3p/SOX4 axis.

Authors:  Xianfang Wang; Jun Shi; Ying Chen; Caihong Wang; Huifang Shi; Xuefang Xie
Journal:  RSC Adv       Date:  2019-11-26       Impact factor: 4.036

2.  Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer.

Authors:  Nouha Setti Boubaker; Aymone Gurtner; Nesrine Trabelsi; Isabella Manni; Haroun Ayed; Ahmed Saadi; Zeineb Naimi; Meriem Ksontini; Mouna Ayadi; Ahlem Blel; Soumaya Rammeh; Mohamed Chebil; Giulia Piaggio; Slah Ouerhani
Journal:  Mol Biol Rep       Date:  2020-10-31       Impact factor: 2.316

Review 3.  Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.

Authors:  Austin W T Chiang; Hratch M Baghdassarian; Benjamin P Kellman; Bokan Bao; James T Sorrentino; Chenguang Liang; Chih-Chung Kuo; Helen O Masson; Nathan E Lewis
Journal:  J Biomed Sci       Date:  2021-06-22       Impact factor: 8.410

4.  MiR-369-3p participates in endometrioid adenocarcinoma via the regulation of autophagy.

Authors:  Ping Liu; Chengbin Ma; Qiongwei Wu; Wenying Zhang; Cao Wang; Li Yuan; Xiaowei Xi
Journal:  Cancer Cell Int       Date:  2019-07-11       Impact factor: 5.722

5.  miRNA Regulation of NK Cells Antiviral Response in Children With Severe and/or Recurrent Herpes Simplex Virus Infections.

Authors:  Marzena Lenart; Edyta Działo; Anna Kluczewska; Kazimierz Węglarczyk; Anna Szaflarska; Magdalena Rutkowska-Zapała; Marcin Surmiak; Marek Sanak; Anna Pituch-Noworolska; Maciej Siedlar
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

6.  miR-369 inhibits Liver Cancer progression by targeting ZEB1 pathway and predicts the prognosis of HCC patients.

Authors:  Yuwei Dong; Fuxia Li; Junjun Wang; Jiangfeng Hu; Zhenghong Li; Yubei Gu; Yun Feng
Journal:  J Cancer       Date:  2021-03-19       Impact factor: 4.207

Review 7.  MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.

Authors:  Bruno Costa Gomes; José Rueff; António Sebastião Rodrigues
Journal:  Cancer Drug Resist       Date:  2019-09-19

Review 8.  MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin.

Authors:  Maria Konoshenko; Yuriy Lansukhay; Sergey Krasilnikov; Pavel Laktionov
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

9.  Fibroblast‑derived exosomal microRNA‑369 potentiates migration and invasion of lung squamous cell carcinoma cells via NF1‑mediated MAPK signaling pathway.

Authors:  Liping Guo; Baoli Li; Jianjun Yang; Juan Shen; Jinshan Ji; Meijing Miao
Journal:  Int J Mol Med       Date:  2020-05-22       Impact factor: 4.101

10.  Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer.

Authors:  Yubo Tang; Bowen Wu; Shuai Huang; Xinsheng Peng; Xing Li; Xiufang Huang; Wei Zhou; Peigen Xie; Peiheng He
Journal:  Oncol Rep       Date:  2018-10-25       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.